Navigation Links
Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial
Date:9/1/2010

R), a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer announces that its second Phase III trial evaluating microplasmin for the non-surgical treatment of vitreomacular adhesion (VMA) has met its primary endpoint. Importantly, the trial also confirmed the positive results seen in the first Phase III trial with microplasmin. The results of the second Phase III trial (TG-MV-007) were presented for the first time at the American Society of Retina Specialists (ASRS) Annual Meeting by Dr. J. Michael Jumper (West Coast Retina and Medical Group and California Pacific Medical Center, California, USA). The trial recruited 326 patients at 48 centers in Europe and the U.S.

The detailed positive results from the first Phase III trial in the microplasmin MIVI-TRUST program (TG-MV-006) were presented at the World Ophthalmology Congress in Berlin in June 2010. The pooled results of both trials will be presented at the upcoming EURETINA (European Society of Retina Specialists) Congress in Paris, France, on September 4 by Prof. Peter Stalmans (University Hospitals Leuven, Belgium).

In his presentation at ASRS, Dr. Jumper highlighted that the TG-MV-007 study had met its primary endpoint, with 25.3% of the 245 microplasmin treated patients achieving resolution of their VMA at 28 days, compared to 6.2% of the 81 patients who received a placebo injection, a highly statistically significant result (p=0.001). In patients without epiretinal membrane, microplasmin was shown to be even more effective with 34.5% of patients seeing resolution of their VMA at 28 days, compared to 6.4% of placebo treated patients. Epiretinal membrane is a layer of scar tissue which builds up on the macula, making it more difficult to achieve resolution of VMA without surgical intervention. Epiretinal membrane can be easily identified using Optical Coherence Tomography (OCT).


'/>"/>
SOURCE ThromboGenics NV
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. ThromboGenics - Positive Microplasmin Phase II Data Published in Ophthalmology
2. ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
3. Global Phase III Study Results Show Eribulin Meets Primary Endpoint of Overall Survival
4. Resverlogix Phase 1b/2a Study Meets Primary Endpoint
5. SAPHRIS(R) (asenapine) Meets Primary Endpoint in Long-Term Extension Study in Patients With Predominant, Persistent Negative Symptoms of Schizophrenia
6. Xceed Meets HTX/CIHR Grant Milestone: Decreasing Sample-Prep Time From Days to Less Than Eight Hours
7. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
8. Zemea Propanediol Meets U.S. Environmental Protection Agency Design for the Environment Criteria
9. Zemea Propanediol Meets U.S. Environmental Protection Agency Design for the Environment Criteria
10. Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery
11. Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Antonio, TX (PRWEB) August 29, 2014 ... and ISO 13485:2003 certified, GAMP® 5 compliant imaging ... awarded an international Phase II clinical trial to ... lymphoma. , Throughout this trial, Intrinsic Imaging will ... not limited to, protocol and charter development, site ...
(Date:8/28/2014)... 28, 2014 Best Sanitizers, Inc., a ... food processing industry, is asking industry professionals to prepare ... of the E2 soap they’re currently using to the ... . Hand hygiene is critical to fighting cross-contamination ... environment. Six key criteria are identified to evaluate the ...
(Date:8/28/2014)... August 28, 2014 “This kit has an ... screen from 0 to 150 ppb,” said Mark Tess, PhD, ... significant benefit to plant owners and USDA-GIPSA inspection agencies that ... commodities. Testing can take place in a matter of minutes ... the plant test the feed and grain before accepting it, ...
(Date:8/28/2014)... important devices in spintronics, an electronic which is ... but also on their spin and the spin-related ... into magnetic signals and vice versa. Recently, the ... Institute of Physics at Johannes Gutenberg University Mainz ... and Japan, has for the first time realised ...
Breaking Biology Technology:Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2Best Sanitizers, Inc. Asks Food Industry Professionals: With Fall Harvest On the Way, Is Your E2 Hand Soap Up to the Task? 2A new, tunable device for spintronics 2A new, tunable device for spintronics 3
... 10 Pharsight,Corporation (Nasdaq: PHST ), a ... clinical drug development, announced today that it,will release ... which,ended December 31, 2007, after the market closes ... a conference call and webcast on Friday,January 25, ...
... BIRMINGHAM, Alabama,Jan. 10 CANTOX HEALTH SCIENCES INC. ... regulatory consulting firm with,specialized expertise in the areas ... Agriculture, Biotech & Consumer Products announces,the launch of ... their,Pharmaceutical & Healthcare Division., For the past ...
... 10 Caliper Life,Sciences, Inc. (Nasdaq: CALP ... the JPMorgan 26th Annual Healthcare Conference in San ... p.m. PST. Mr.,Hrusovsky will discuss Caliper,s outlook for ... performance for 2007., Based on preliminary, unaudited ...
Cached Biology Technology:Pharsight Announces Fiscal Third Quarter 2008 Earnings Release Date and Conference Call 2Cantox Announces the Launch of Ashuren Health Sciences Pharmaceutical Division 2Caliper Life Sciences to Present at JPMorgan 26th Annual Healthcare Conference Today 2
(Date:8/29/2014)... and number of connections in transcription factor networks (TFNs) ... a study published in PLOS Computational Biology ... signature contributes to a network,s resilience against mutations. ... assortativity of TFN models has a greater effect on ... of assortativity," said Dov A. Pechenick, PhD, lead author ...
(Date:8/29/2014)... . The ... oldest form of communication. Acting as messenger molecules, pheromones ... attraction between males and females. Fish rely on pheromones ... in males and females. Scientists at the Marine Science ... Portugal, and at the Max Planck Institute for Chemical ...
(Date:8/29/2014)... MO. - In a cell,s nucleus, chromosomal DNA ... histones, an amalgam biologists call chromatin. Until about ... nuclear "sidekick," the mere packing material around which ... biologists have developed a greater appreciation for how ... investigators from multiple research institutions studying the sequence ...
Breaking Biology News(10 mins):Assortativity signatures of transcription factor networks contribute to robustness 2Ready for mating at the right time 2Ready for mating at the right time 3'K-to-M' histone mutations: How repressing the repressors may drive tissue-specific cancers 2'K-to-M' histone mutations: How repressing the repressors may drive tissue-specific cancers 3
... SANTA CRUZ, CA--The emerging field of "personalized" or ... cancer. If scientists can identify the genetic changes that ... information to develop targeted treatments. But achieving this goal ... and a sophisticated infrastructure to manage and analyze the ...
... stunning observation of the architecture within a cell ... changes during the formation of gametes, also known as ... process. The findings by the international team led ... treatment of disorders caused by a misregulation of cellular ...
... April 30, 2012 -- Autism has a strong genetic basis, ... had mixed results. The reason for this is that autism ... involved in different individuals, making it hard to find the ... the Hebrew University of Jerusalem has shown that despite this ...
Cached Biology News:UC Santa Cruz builds national data center for cancer genome research 2UC Santa Cruz builds national data center for cancer genome research 3UC Santa Cruz builds national data center for cancer genome research 4UC Santa Cruz builds national data center for cancer genome research 5Scientists make stunning inner space observations 2Scientists make stunning inner space observations 3Researchers at Hebrew University identify genetic systems disrupted in autistic brain 2
Rabbit polyclonal to ZA20D3 ( Abpromise for all tested applications). entrezGeneID: 54469 SwissProtID: Q6FIF0...
P8B1...
Goat polyclonal to Sarcosine Oxidase ( Abpromise for all tested applications). Antigen: Microbial Sarcosine Oxidase. Entrez Gene ID: 51268 Swiss Protein ID: Q6IAJ9...
Rabbit polyclonal to XPC ( Abpromise for all tested applications). Antigen: Synthetic peptide from N-terminus of Human XPC conjugated to a carrier protein Entrez Gene ID: 7508 Swiss ...
Biology Products: